An additional regulatory application is also under review in the european union, with a decision expected by the first half of 2026. Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo See important safety & full prescribing information.
Jameliz OnlyFans
Cemiplimab is the first immunotherapy approved for adjuvant treatment in cscc, offering a new option for patients at high risk of recurrence.
